A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults
A Phase 1, Randomized, Double-Blind, Dose-Escalation Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of MGAWN1, a Neutralizing, Humanized, Monoclonal Antibody (IgG1k) to West Nile Virus, in Healthy Adults
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Maryland
-
Baltimore、Maryland、美国、21225
- PAREXEL Phase 1 Unit
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Written informed consent obtained from the subject including consent for the use of research-related health information, before performance of any study-related procedure including screening procedures
- Healthy adult male or female subjects aged 18-65 years, with a body mass index (BMI) of 18-32 kg/m2
Subjects must be physically healthy as determined by the investigator based on medical history, physical examination, ECG, and clinical laboratory tests within laboratory normal ranges. To be considered normal, the following results must pertain:
- The serum potassium must be within normal limits.
- Hemoglobin must be ≥12 mg/dl; ANC must be 1,500-upper limit of normal (ULN); platelets must be 130,000-500,000 μL; and sodium must be 130-150 moles/L.
- Each of these tests must not exceed the upper limit of normal: WBC, creatinine, and (provided asymptomatic) fasting blood glucose.
- Bilirubin must be ≤ 2x ULN, ALT ≤ 1.25x ULN, and AST ≤1.25x ULN
- Urinalysis: glucose negative and protein ≤ 20 mg/dl.
- Have adequate venous access
- Have negative assays for human immunodeficiency virus (HIV), hepatitis B virus (HBsAg) and hepatitis C virus (HCV)
- Women of childbearing potential will not be breastfeeding and will have a negative serum pregnancy test within 21 days of study drug administration as well as on Study Day -1
- Women of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year of enrollment) must be using appropriate birth control (defined as a method with low failure rate, i.e., less than 1% per year, when used consistently and correctly such as implants, injectables, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner) during the entire duration of study participation. Use of contraceptive medications is allowed during the study. Women who have undergone a total hysterectomy or are postmenopausal are eligible.
- In the opinion of the investigator, the subject is capable of understanding and complying with the protocol
- Subject is a non-smoker, i.e., has refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc. for 6 months before study entry
- Subject's normal alcohol consumption does not exceed 3 units per day if male or does not exceed 2 units per day if female. Both male and female subjects will be permitted to consume no more than 2 units of alcohol per day throughout the study. (One unit of alcohol is equivalent to 1 ounce of hard liquor, or 4 ounces of wine, or 12 ounces of beer.)
- Willing to forego other forms of experimental treatment during the study
Exclusion Criteria:
- Subject is unwilling or unable to comply with the protocol during the study period or to cooperate fully with the investigator or the site personnel
- Subject has a significant organ abnormality or disease
- Subject is considering or scheduled to have any surgical procedure during the duration of the study
- Subject has an active malignancy or history of solid, metastatic, or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed
- Subject has donated or lost more than a unit of blood within 30 days before screening
- Subject has a positive qualitative urine drug test at screening or an abnormal blood alcohol test (≥ 10mg/dL) on Study Day -1
- Subject has received any other investigational drug or investigational biologically derived pharmaceutical agent within 60 days before screening
- Subject has a history of seizure, chronic headache, viral encephalitis, or clinically significant infection (including viral) in the 14 days before dosing
- Subject is receiving any concomitant medication requiring a prescription, except for contraceptives
- Use of OTC preparations, herbal remedies or nutritional supplement (other than calcium and vitamin D) within the 7 days before study drug administration
- Subject has ongoing drug abuse/dependence (including alcohol); or recent history (over the past 5 years) of, or treatment for, alcohol or drug abuse
- Subject has a significant allergy to food or drugs
- Currently symptomatic seasonal allergies, or history of anaphylaxis, asthma, dermatographism or eczema
- Subject has any condition(s) that in the investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study
- Subject is unable to understand spoken and/or written English or any other language in which a certified translation of the informed consent is available
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:1a
Cohort 1 completed
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
|
安慰剂比较:1b
Cohort 1 placebo completed
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
Single IV dose
|
实验性的:2a
Cohort 2 completed completed
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
|
安慰剂比较:2b
Cohort 2 placebo completed
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
Single IV dose
|
实验性的:3a
Cohort 3 active
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
|
安慰剂比较:3b
Cohort 3 placebo
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
Single IV dose
|
实验性的:4a
Cohort 4 active
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
|
安慰剂比较:4b
Cohort 4 placebo
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
Single IV dose
|
实验性的:5a
Cohort 5 active
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
|
安慰剂比较:5b
Cohort 5 placebo
|
Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control. Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Single IV dose
Single IV dose
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
The incidence of adverse events and serious adverse events through the end of the study.
大体时间:6 months
|
6 months
|
次要结果测量
结果测量 |
大体时间 |
---|---|
The determination of pharmacokinetic (PK) parameters and immunogenicity of MGAWN1.
大体时间:6 months
|
6 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
西尼罗河病毒的临床试验
MGAWN1的临床试验
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)不再可用
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)终止脑炎 | 脑膜炎 | 西尼罗病毒感染 | 西尼罗河热 | 西尼罗神经侵袭性疾病 | 急性弛缓性麻痹